Feng Chi Biotech Past Earnings Performance
Past criteria checks 1/6
Feng Chi Biotech has been growing earnings at an average annual rate of 2.5%, while the Healthcare industry saw earnings growing at 7.1% annually. Revenues have been growing at an average rate of 1% per year. Feng Chi Biotech's return on equity is 8.3%, and it has net margins of 11.1%.
Key information
2.5%
Earnings growth rate
1.6%
EPS growth rate
| Healthcare Industry Growth | 9.1% |
| Revenue growth rate | 1.0% |
| Return on equity | 8.3% |
| Net Margin | 11.1% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How Feng Chi Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 173 | 19 | 46 | 13 |
| 31 Mar 24 | 177 | 21 | 45 | 13 |
| 31 Dec 23 | 181 | 23 | 43 | 12 |
| 30 Sep 23 | 182 | 23 | 43 | 12 |
| 30 Jun 23 | 184 | 24 | 43 | 12 |
| 31 Mar 23 | 189 | 24 | 44 | 12 |
| 31 Dec 22 | 193 | 25 | 44 | 12 |
| 30 Sep 22 | 190 | 23 | 44 | 13 |
| 30 Jun 22 | 187 | 21 | 44 | 14 |
| 31 Mar 22 | 185 | 22 | 45 | 14 |
| 31 Dec 21 | 183 | 23 | 45 | 14 |
| 30 Sep 21 | 181 | 25 | 46 | 13 |
| 30 Jun 21 | 179 | 26 | 47 | 12 |
| 31 Mar 21 | 179 | 26 | 46 | 12 |
| 31 Dec 20 | 179 | 25 | 45 | 12 |
| 30 Sep 20 | 181 | 25 | 44 | 12 |
| 30 Jun 20 | 182 | 24 | 42 | 12 |
| 31 Mar 20 | 178 | 21 | 41 | 13 |
| 31 Dec 19 | 174 | 17 | 39 | 13 |
| 30 Sep 19 | 171 | 17 | 39 | 13 |
| 30 Jun 19 | 167 | 16 | 39 | 13 |
| 31 Mar 19 | 158 | 17 | 38 | 14 |
| 31 Dec 18 | 148 | 17 | 37 | 14 |
| 31 Dec 17 | 125 | 13 | 36 | 8 |
| 31 Dec 16 | 140 | 16 | 41 | 5 |
Quality Earnings: 6744 has a high level of non-cash earnings.
Growing Profit Margin: 6744's current net profit margins (11.1%) are lower than last year (13.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6744's earnings have grown by 2.5% per year over the past 5 years.
Accelerating Growth: 6744's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 6744 had negative earnings growth (-20%) over the past year, making it difficult to compare to the Healthcare industry average (6.3%).
Return on Equity
High ROE: 6744's Return on Equity (8.3%) is considered low.